The γ-Aminobutyric Acid Type A (GABA<sub>A</sub>) Receptor Activation Modulates Tau Phosphorylation*<sup>1,3,4</sup>

Received for publication, September 30, 2011, and in revised form, January 8, 2012. Published, JBC Papers in Press, January 10, 2012, DOI 10.1074/jbc.M111.309385

Niko-Petteri Nykänen<sup>1</sup>, Kai Kysenius<sup>5</sup>, Prasanna Sakha<sup>3</sup>, Päivi Tammela<sup>5</sup>, and Henri J. Huttunen<sup>1</sup><sup>1</sup>

From the<sup>1</sup>Neuroscience Center and the<sup>5</sup>Center for Drug Research, Faculty of Pharmacy, University of Helsinki, Helsinki FIN-00014, Finland

**Background:** Tau phosphorylation regulates its functions and is increased in Alzheimer disease.

**Results:** Novel live cell assay of Tau protein-protein interaction with Pin1 showed that GABA<sub>A</sub> receptor activity regulates Tau phosphorylation.

**Conclusion:** GABA<sub>A</sub> receptor activity is associated with regulation of Tau phosphorylation.

**Significance:** Learning about Tau regulation and functions is crucial for understanding basic neurobiology, as well as mechanisms of neurodegeneration.

Abnormal phosphorylation and aggregation of the microtubule-associated protein Tau are hallmarks of various neurodegenerative diseases, such as Alzheimer disease. Molecular mechanisms that regulate Tau phosphorylation are complex and currently incompletely understood. We have developed a novel live cell reporter system based on protein-fragment complementation assay to study dynamic changes in Tau phosphorylation status. In this assay, fusion proteins of Tau and Pin1 (peptidyl-prolyl cis-trans-isomerase 1) carrying complementary fragments of a luciferase protein serve as a sensor of altered protein-protein interaction between Tau and Pin1, a critical regulator of Tau dephosphorylation at several disease-associated proline-directed phosphorylation sites. Using this system, we identified several structurally distinct GABA<sub>A</sub> receptor modulators as novel regulators of Tau phosphorylation in a chemical library screen. GABA<sub>A</sub> receptor activation promoted specific phosphorylation of Tau at the AT8 epitope (Ser-199/Ser-202/Thr-205) in cultures of mature cortical neurons. Increased Tau phosphorylation by GABA<sub>A</sub> receptor activity was associated with reduced Tau binding to protein phosphatase 2A and was dependent on Cdk5 but not GSK3β kinase activity.

Many neurodegenerative diseases are characterized by cerebrovascular accumulation of proteinaceous aggregates. Neurodegenerative tauopathies are a group of disorders that includes Alzheimer disease (AD)<sup>2</sup> and frontotemporal dementias (1, 2).

<sup>*This work was supported by grants from the Academy of Finland, Sigrid Jusélius Foundation, Biocentrum Helsinki, and Finnish Cultural Foundation. The research leading to these results has received funding from the European Union’s Seventh Framework Programme (FP7/2007-2011) under Grant Agreement 206918. H. J. H. is a cofounder, employee and shareholder of Hermo Pharma Ltd.</sup>

<sup>1</sup>This article contains supplemental Tables S1 and S2.

<sup>1</sup>To whom correspondence should be addressed: Neuroscience Center, P.O. Box 56 (Viikinkaari 4), University of Helsinki, Helsinki, FIN-00014 Finland. Tel.: 358-9-191-57616; Fax: 358-9-191-57620; E-mail: Henri.Huttunen@helsinki.fi.

<sup>2</sup>The abbreviations used are: AD, Alzheimer disease; BZ, benzodiazepine; Cdk5, cyclin-dependent kinase 5; GABA<sub>R</sub>, γ-aminobutyric acid receptor subtype A; hGluc, humanized G. princeps luciferase; GSK3β, glycogen synthase kinase-3β; MT, microtubule; PCA, protein-fragment complementa-

**Significance:** Tauopathies share a common neuropathological hallmark, the neurofibrillary tangles that are composed of aberrantly phosphorylated forms of the microtubule (MT)-associated protein Tau. Mutations in the MAPT gene encoding the Tau protein have been associated with neurodegenerative diseases, such as familial frontotemporal dementia with parkinsonism linked to chromosome 17q21 (FTDP-17) (3). Despite their diverse disease phenotypes, degeneration of neurons and the resulting brain dysfunction in tauopathies is linked to deregulation of Tau phosphorylation and progressive intraneuronal accumulation of filamentous Tau inclusions.

In addition to its well established microtubule binding role, various cell signaling functions of Tau have been reported (reviewed in Ref. 4). Tau can modulate various neuronal functions, such as cytoskeletal reorganization, axonal transport, NGF signaling, stress response, and neurogenesis. In healthy neurons a spatial gradient of Tau, whose concentration is greater in axons than in somatodendritic compartments, is maintained. In neurodegenerative diseases, such as AD, the gradient becomes inverted, potentially disrupting normal microtubule-associated functions such as axonal transport (5, 6). Recent reports suggest that hyperphosphorylation-induced dendritic (mis)localization of Tau may directly cause synaptic abnormalities in the dendritic spines (7) and also promote synaptotoxicity of β-amyloid (8), a central pathogenic peptide accumulating in the brains of AD patients. Interestingly, changes in Tau phosphorylation status leading to Tau pathology have a temporally specific sequence (9, 10).

There are 84 potential serine and threonine phosphate acceptor residues in the longest human Tau isoform, of which ~30 have been reported to be phosphorylated in vivo (1). The phosphorylation sites are located in regions close to the MT binding repeats, and it has been well established that increased Tau phosphorylation negatively regulates MT binding. Because of the central involvement of aberrant Tau phosphorylation in many neurodegenerative diseases, significant research efforts have
focused on the protein kinases and protein phosphatases that regulate Tau phosphorylation. Currently, it is unclear whether all of them participate in Tau phosphorylation under physiological or pathological conditions in vivo (2). From the drug target perspective, particular attention has been paid to two proline-directed kinases, glycogen synthase kinase 3β (GSK3β) and cyclin-dependent kinase 5 (Cdk5), as Tau kinases. Proline-directed kinases phosphorylate Tau at 14 serine-proline (SP) or threonine-proline (TP) motifs located in the proline-rich regions flanking the microtubule binding domains of Tau (11, 12). Because phosphorylation at SP/TP sites of Tau is a striking feature in patients with AD and other tauopathies, these sites are commonly referred to as “disease-associated” sites.

A number of phosphatases, including protein phosphatase (PP)1, PP2A, PP2B, and PP5, that mediate Tau dephosphorylation have been identified, but the exact role(s) of these phosphatases under physiological and pathological conditions remain to be addressed. Importantly, proline can adopt two completely different conformational states, providing a phosphorylation-dependent structural switch (13). Peptidyl-prolyl cis/trans-isomerase (PPIase) Pin1 (protein interacting with NIMA (never in mitosis A)-1) is a phosphorylation-specific PPIase that controls the access of phosphorylases to proline-directed phosphopeptidites (14, 15). Pin1 promotes dephosphorylation of Tau at the SP/TP sites via trans-specific PP2A, and in Pin1 knock-out mice Tau is hyperphosphorylated in several SP/TP sites (16). Cis-pTau is resistant to SP/TP-dephosphorylation, and compromised Pin1 activity in neurons leads to a loss of MT binding, hyperphosphorylation of Tau, and formation of neurofilibrillary tangles. Therefore, Pin1 is a critical regulator of Tau dephosphorylation and restores Tau function by catalyzing cis- to trans-isomerization (17).

Various approaches have been used to identify compounds with the potential to modulate Tau phosphorylation as a disease-modifying strategy in neurodegenerative diseases (2). Here, we have developed a dynamic assay system capable of measuring protein-protein interactions (PPIs) of Tau in live cells. A luminescence-based protein-fragment complementation assay (PCA) (or bimolecular luminescence complementation) using split humanized Gaussia princeps luciferase (hGLuc) (18) was developed for dynamic detection of Tau PPIs in cells. We used Tau and Pin1 as a reporter pair to screen a focused library of pharmaceutical compounds to test functionality of the Tau-based PCA. Several GABA_A receptor modulators were found to increase Tau-Pin1 interaction. Importantly, these compounds significantly increased Tau phosphorylation at the AT8 epitope (Ser-199/Ser-202/Thr-205) in mature rat cortical neurons in a Cdk5-dependent manner. Tau phosphorylation at Ser-199/Ser-202/Thr-205 remained elevated at least for 24 h after washout of the drugs. These data suggest that hGLuc PCA is a dynamic and sensitive live cell assay to measure Tau PPIs and identify novel modulators of Tau phosphorylation. Our data suggest that GABA_A activity and regulation of Tau phosphorylation are connected via a mechanism that involves both Cdk5 and PP2A.

**EXPERIMENTAL PROCEDURES**

**Chemicals**—The Pin1 inhibitor used in this study was 5-hydroxy-1,4-naphtoquinone (juglone) from Sigma. Cdk5 (roscovitine) and PP2A inhibitors (calyculin A) were from Calbiochem. GSK3β inhibitor (SB216763) and GABA receptor modulators (muscimol, picrotoxin, and bicuculline) were purchased from Tocris.

**DNA Constructs**—The hGLuc expression plasmids were constructed in the pcDNA3.1/zeo (Invitrogen) backbone. The original humanized G. princeps PCA plasmids (18) were donated by Prof. Stephen Michnick (Université de Montréal, Montreal, Canada). The human cDNAs for Tau (GenBank accession number BC114948; ON4R), Pin1 (GenBank accession number NM_006221), GSK3β (GenBank accession number BC000251), regulatory β subunit of PP2A (GenBank accession number BC041071), and p35 (GenBank accession number BC020580) were purchased from Open Biosystems/Thermo Scientific. In all the hGLuc PCA constructs used in this study, the hGLuc fragment was placed in the C terminus separated by a (GGGGS)₅G linker. The fusion protein design is graphically summarized in Fig. 1A. The cDNA for human GSK3β was PCR-cloned to pcDNA3 vector (Invitrogen) using EcoRI-Xhol restriction sites. The identity of all constructs was confirmed by DNA sequencing. pEGFP-tubulin plasmid encoding human α-tubulin fused with EGFP was from Clontech.

**Cell Culture and Transfection**—Mouse Neuro-2A (N2a) neuroblastoma cells (ATCC) were grown in DMEM supplemented with 10% (v/v) FBS (Invitrogen), 1% (v/v) l-glutamine-penicillin-streptomycin solution (Lonza) at 37°C in a water-saturated air, 5% CO₂ atmosphere. N2a cells were transfected with JetPEI (Polyplus) according to the manufacturer’s instructions. For the primary neuronal cultures, the cortex was dissected from E18 rat embryos, and the tissue dissociated in papain solution (50 μg/ml in 10 mg of dl-cysteine-HCl 10 mg of BSA, 250 mg of glucose, and 50 ml of PBS for 10 min at 37°C). Next, the cells were triturated and suspended in a medium containing 9.8 ml of Ca²⁺/Mg²⁺ free Hanks’ balanced salt solution, 1 mxi sodium pyruvate, 10 mM HEPES, and 10 μl of DNase I. The cells were plated onto poly-l-lysine coated 12-well culture plates at a cell density of 400 000 ml⁻¹. The cells were maintained in neurobasal medium containing 2% B27 supplement, 1% penicillin-streptomycin, and 1% glutamine (5% CO₂, 37°C). Primary neurons at DIV 21–22 were treated with selected compounds for 6–48 h before assessment of Tau phosphorylation on Western blots.

**Protein-Fragment Complementation Assay**—N2a cells were plated on poly-l-lysine-coated white-wall 96-well plates (PerkinElmer Life Sciences). 100 ng of plasmid DNA was used for transient transfection per well, divided as follows: 47.5 ng of GLuc1 reporter plasmid, 47.5 ng of GLuc2 reporter plasmid, and 5 ng of pRC/CMV-β-galactosidase (βGal) as an internal vector control. Experiments were carried out 48 h post-transfection in serum-free conditions. Briefly, the cells were washed with PBS and changed to phenol red-free DMEM (Invitrogen) without serum. Test compounds were added to this medium, and the cells were incubated for 2–4 h. MexSO₄ was used as vehicle control. To detect the hGLuc PCA signal, the cells were injected well-by-well with 25 μl (final concentration, 20 μM) of native coelenterazine (Nanolight Technology), and emitted luminescence was detected immediately by flash luminometry using a Victor³ plate reader (PerkinElmer Life Sciences). Four replicate wells were used per experiment. Individual experi-
compounds were obtained mostly from commercial sources. Drug metabolites and other pharmaceutical reagents. These clinically approved drugs in different therapy areas, as well as some focused chemical library used in this study contained 240 clinical entities.

The cleavage buffer (120 mM sodium phosphate, pH 7.0, 24 mM KCl, 2.4 mM MgSO₄, and 2.4 mM DTT), and 100 μl of this solution was added per well. The plates were incubated at +37 °C for a further 30 min. Finally, absorbance was read at 405 nm. PCA signals were normalized to βGal signals/well.

**Screening of Pharmaceutical Compound Library**—The focused chemical library used in this study contained 240 clinically approved drugs in different therapy areas, as well as some drug metabolites and other pharmaceutical reagents. These compounds were obtained mostly from commercial sources and stored as 10 μM stock solutions in Me₂SO in a 96-well plate format. PCA screening was carried out with Pin1-GLuc1 and Tau-GLuc2 as reporters (50 ng + 50 ng of plasmids/well) in 96-well plates. The procedure followed the general PCA protocol described above with the following exceptions: no βGal internal vector control-based PCA signal normalization was performed, and plates were injected with coelenterazine and read with Varioskan Flash multimode plate reader (Thermo Fisher Scientific). Library compounds were diluted into assay media and added to the cells in final concentration of 50 μM by using a Biomek FX liquid handling work station (Beckman Coulter). The cells were incubated for 2 h at 37 °C before PCA analysis. Me₂SO was used as vehicle control and 5 μM juglone as a negative control. Four replicate wells/compound were used. After primary screening, secondary testing and dose-response experiments (2-fold dilution series with five concentrations starting from 50 μM) were carried out with a selected set of compounds using freshly prepared stock solutions.

**Live Cell Detection of Pin1-Tau Protein-Protein Interaction with hGLuc PCA**—Because Pin1 is a critical regulator of PP2A-mediated phosphorylation of Tau, we hypothesized that detection of Pin1-Tau interaction by a luminescence-based PCA may serve as a good starting point for developing live cell Tau PPI assays. We chose a recently developed variant of the PCA that is based on humanized form of G. princeps luciferase (hGLuc) (18) to develop a live cell assay that would be suitable for high throughput purposes. Various fusion constructs using the complementary GLuc fragments were generated (Fig. 1A) and tested in N2a mouse neuroblastoma cells. Identity and expression of the PCA constructs were verified by DNA sequencing and Western blotting (Fig. 1C). To assess the normal functionality of the Tau-GLuc2 fusion protein, we analyzed its subcellular localization by immunofluorescence microscopy. Localization to neurites and cytoskeletal structures together with GFP-tubulin suggests that the hGLuc fusion tag does not interfere with normal cellular localization and functions of Tau (Fig. 1B).

To test whether the Pin1-Tau PCA signal, indicative of protein-protein interaction between the two proteins, is responsive to Pin1 inhibition, we treated the cells with juglone for 2 h and then measured Pin1-Tau PCA signal. Juglone is a natural compound and a selective, cell-permeable, and irreversible inhibitor of parvulin-like PPIases, such as *Escherichia coli* parvulin and human Pin1 (IC₅₀ of ~1.5 μM) (19). As shown in...
**GABA**<sub>A</sub> Receptor Activation Modulates Tau Phosphorylation

Fig. 2A, juglone dose-dependently decreased Pin1-Tau interaction in N2a cells as measured with hGLuc PCA. Maximal inhibition (86%) was achieved at 5 μM juglone concentration.

Glycogen synthase kinase-3β (GSK3β) is one of the central Tau kinases (2, 20), and its overexpression in mammalian cells results in increased Tau phosphorylation in several sites including the AT8 epitope (21). We measured Pin1-Tau interaction by PCA in cells cotransfected with empty mock plasmid or plasmid encoding GSK3β. As shown in Fig. 2B, overexpression of GSK3β nearly doubled Pin1-Tau interaction as measured by the PCA. This effect was abolished if the GSK3β-expressing cells were treated with a specific GSK3β inhibitor SB216763. Western blots of N2a cells transfected with Tau-GLuc2 alone or together with GSK3β nearly doubled Pin1-Tau interaction as measured by the PCA. This effect was abolished if the GSK3β-expressing cells were treated with a specific GSK3β inhibitor SB216763. Western blots of N2a cells transfected with Tau-GLuc2 alone or together with GSK3β showed that GSK3β overexpression promotes phosphorylation of the Tau-GLuc2 fusion protein in at least AT8 and PHF13 epitopes (Fig. 2C). These functional validation data suggest that the Pin1-Tau PCA reporter system responds bidirectionally to stimuli that alter either Pin1 or Tau status in the cells.

**Screening of Small Molecule Modulators of Tau-Pin1 Interaction with hGLuc PCA** — Next, we screened a focused library of 240 pharmaceutical compounds to identify modulators of Tau-Pin1 interaction. Before the screen, the Tau-Pin1 PCA assay was optimized for parameters, such as vehicle (Me<sub>2</sub>SO) tolerance and intra- and interplate variance of signal (data not shown). Four replicate wells were used. The primary screen yielded 25 initial hits of which 21 increased (PCA signal more than 200% of control) and four decreased (PCA signal less than 75% of control) the Pin1-Tau interaction compared with vehicle-treated control (Table 1 and supplemental Table S1). The relatively high hit rate (10.4%) may be partially explained by the focused nature of the library. Also, cell-based screens tend to have higher hit rates than biochemical screens. Two compounds were determined to be incompatible with flash lumino-

<sup>3</sup> P. Sakha, P. Tammela, and H. J. Huttunen, unpublished data.
GABA<sub>A</sub> Receptor Activation Modulates Tau Phosphorylation

Two compound classes were strongly presented among the hits. Sedative-hypnotics and sulfonamide antibacterials presented 43% of all hit compounds increasing the Pin1-Tau signal. The activity of benzodiazepines and barbiturates was confirmed in secondary testing and dose-response experiments, whereas a consistent effect of sulfonamides could not be verified in the follow-up studies (supplemental Table S2). Depending on the sedative, the average increase in Pin1-Tau interaction varied between 1.4- and 2.0-fold as compared with vehicle-treated cells. Desalkylflurazepam, an active metabolite of the benzodiazepine flurazepam, and butethal, a barbiturate, were chosen as representative sedative hit compounds for further studies. As shown in Fig. 3A, both compounds elicited a dose-dependent increase in Pin1-Tau interaction.

Benzodiazepines (BZ) and barbiturates are widely used sedatives and hypnotics that promote the binding of the major inhibitory neurotransmitter GABA to the GABA<sub>A</sub> receptors enhancing the GABA-induced ionic currents through these ligand-gated chloride channels (22, 23). Because N2a cells are known to express functional GABA<sub>A</sub> receptors (24) and both barbiturates and BZ were found among the hit compounds, it is likely that the increased Pin1-Tau interaction results from increased GABA signaling. To confirm this, we used muscimol, a psychoactive alkaloid and a selective agonist of the GABAA receptors, in Pin1-Tau PCA in N2a cells. We also tested whether picrotoxin, a noncompetitive antagonist and channel blocker of GABA<sub>A</sub> receptors, could block the effect of muscimol. After a 2-h treatment, 100 nM muscimol increased Pin1-Tau PCA signal by nearly 2-fold (Fig. 3B), confirming that increased GABA<sub>A</sub> receptor activity enhances Pin1-Tau interaction in N2a cells. Moreover, this effect of muscimol was completely blocked by 1 μM picrotoxin, suggesting that the effect of muscimol was specific and dependent on GABA<sub>A</sub>R activity.

Only four of the 25 hit compounds decreased Pin1-Tau interaction (supplemental Tables S1 and S2). We tested one of these compounds, folic acid, in secondary assays. As shown in Fig. 3C, folic acid caused a dose-dependent decrease in Pin1-Tau interaction, with a maximal ~40% effect, as measured by the Pin1-Tau PCA. Interestingly, folate deficiency has been shown to promote Tau phosphorylation in both neuroblastoma cells and in mouse brain (25).

**Pharmacological Modulation of GABA<sub>A</sub> Receptor Promotes Tau Phosphorylation at Ser-199/Ser-202/Thr-205 in Neurons**—Next, we tested whether the GABA<sub>A</sub> modulators identified in the screen affect Tau phosphorylation in mature cortical neurons. Phosphorylation of Tau in Pin1<sup>−/−</sup> mouse brain is significantly increased in several proline-directed sites relevant to AD pathology, including the AT8, AT180, TG3, MC1, and Alz50 epitopes (16). Because the hit compounds identified in the Pin1-Tau PCA screen may be specific for certain phosphoepitopes recognized by Pin1, we used antibodies AT8 and TG3 that detect Tau phosphorylated at Ser-199/Ser-202/Thr-205 and Thr-231/Ser-235, respectively. As a third antibody we used PHF13 (Ser 396). AT8 and TG3 epitopes but not the PHF13 were reported to be hyperphosphorylated in the Pin1<sup>−/−</sup> mouse brain (16). The effects of desalkylflurazepam and butethal were tested in cultures of mature (DIV 21) rat cortical neurons that are known to display synaptic activity and GABAergic responses (26, 27). Neurons were treated with increasing concentrations of desalkylflurazepam or butethal for 6 h in normal culture medium and then analyzed for Tau phosphorylation on Western blots. As shown in Fig. 4 (A and B), both compounds increased Tau phosphorylation specifically at the AT8 epitope with no effect on the TG3 and PHF13 epitopes. Desalkylflurazepam appeared to be more potent in these experimental conditions as compared with butethal with a maximum increase of 72% at 1 μM.

**TABLE 1**

Summary of results from Pin1-Tau PCA screen

| Compounds screened | 240 |
|--------------------|-----|
| Total number of hits | 27  |
| Total number of excluded hits based on assay incompatibility | 2   |
| Hit rate (%) | 10.4 |
| Total number of compounds increasing the interaction | 21  |
| Total number of compounds decreasing the interaction | 4   |
| Most commonly repeated drug classes |
| Sedatives (barbiturates or benzodiazepines) | 5   |
| Sulfonamide antibacterials | 4   |

**FIGURE 3. Validation of hit compounds with GLuc-based PCA for detection of Tau-Pin1 interaction.** N2a cells were transiently transfected with Pin1-GLuc1 and Tau-GLuc2 constructs. 48 h post-transfection, the cells were treated for 2 h with increasing concentrations of desalkylflurazepam or butethal (A) or folic acid (C). In B, cells were treated for 2 h with either 100 nM muscimol or with 100 nM muscimol together with 1 μM picrotoxin. Luminescence signal was measured by flash luminometry in live cells. The luminescence values were normalized by corresponding data from β-galactosidase assay (internal vector control, per well). The average values are displayed as percentages of change as compared with vehicle-treated control cells (means ± S.E.; n = 3). * indicates significant differences with p < 0.05, ** and *** indicate significant differences with p < 0.01, and p < 0.001, respectively.
GABA_A Receptor Activation Modulates Tau Phosphorylation

A primary rat cortical neurons (21 DIV) were treated with 50 μM butethal (BUT) and desalkylflurazepam (DAF) for 48 h or treated for 24 h followed by a 24-h washout period. As a control, the neurons were treated with vehicle only. The samples were analyzed as in Fig. 4A, Veh, vehicle.

To understand the stability of the effect of GABA_A receptors on Tau phosphorylation, we next performed a washout experiment. 21 DIV cortical neurons were treated with 50 μM desalkylflurazepam or butethal for 48 h or treated for 24 h followed by a 24-h washout period before the analysis of Tau phosphorylation. The phosphorylation at the AT8 epitope remained at an elevated level even after the 24-h washout (Fig. 4C). These results suggest that GABA_A activity can cause a specific increase of Tau phosphorylation at the AT8 epitope, and this effect remains even after a 24-h washout period.

GABA_A Receptor Modulators Do Not Affect PP2A Activity in Cell-free System but Reduce PP2A-Tau Interaction in Live N2a Cells—A recent study found that anesthesia promotes hyperphosphorylation of Tau in several epitopes, including AT8 (28). The authors suggested that the anesthesia effect on Tau phosphorylation was due to PP2A inhibition, likely because of anesthesia-induced hypothermia. On the other hand, barbiturates have been shown to directly inhibit phosphatases, such as calcineurin/PP2B, another phosphatase associated with Tau dephosphorylation (29). We used an in vitro PP2A assay to test direct effects of desalkylflurazepam and butethal on PP2A activity. As shown in Fig. 5A, no effects on PP2A activity were detected using desalkylflurazepam or butethal, whereas calyculin A (PP2A inhibitor) significantly reduced PP2A activity in this cell-free enzyme activity assay.

Next, we generated a PP2A PCA reporter with GLuc1 fusion attached to the regulatory βα subunit of PP2A. The PP2A-Tau PCA assay was first pharmacologically validated with juglone. As expected based on previous reports (30–32), inhibition of Pin1 activity in cells by juglone reduced PP2A interaction with Tau (Fig. 5B). When N2a cells expressing PP2A-Tau PCA reporters were treated with desalkylflurazepam and butethal, nearly ~50% reduction in PP2A-Tau interaction was found (Fig. 5C). These data suggest that although GABA_A receptor modulators do not directly affect PP2A enzyme activity, the interaction of PP2A with Tau in intact cells is reduced when GABA_A is activated.

Cdk5 but Not GSK3β Mediates GABA_A Receptor Activity-induced Phosphorylation of Tau—Phosphorylation of Tau is catalyzed by a large number of kinases (2). The AT8 epitope (Ser-199/Ser-202/Thr-205) can be phosphorylated by at least GSK3β, Cdk5, PKA, and ERK1/2 (4). GSK3β and Cdk5 are often considered as prime candidates mediating aberrant Tau phosphorylation at disease-associated sites. Moreover, GSK3β, Cdk5, and PP2A have been reported to associate in a functional complex (33) and cross-regulate each other’s activities (34). We tested whether GSK3β or Cdk5 inhibition could affect the ability of GABA_A receptor activation to enhance Tau phosphorylation. SB216763, a GSK3β inhibitor, and roscovitine, a Cdk5 inhibitor, were used together with desalkylflurazepam in 21 DIV cortical neuron cultures. Muscimol and bicuculline, a competitive GABA_A antagonist, were used as positive and negative controls. Although SB216763 had no effect, roscovitine effectively inhibited desalkylflurazepam-induced Tau phosphorylation at the AT8 epitope (Fig. 6A). This indicates that Cdk5 but not GSK3β activity mediates the effects of GABA_A receptor activity on Tau. In accordance with these data, no change in GSK3β serine 9 phosphorylation status was found in desalkylflurazepam-treated neurons (Fig. 6A).

Finally, we modulated Cdk5 activity in N2a cells to measure its effects on Pin1-Tau interaction. For this purpose, we overexpressed p35, the activating regulatory subunit of Cdk5 (35, 36), in parallel Pin1-Tau PCA reporter constructs. In agreement with previously published data, overexpression of p35 in
GABA<sub>A</sub> Receptor Activation Modulates Tau Phosphorylation

N2a cells enhanced Pin1-Tau interaction indicative of increased Tau phosphorylation (Fig. 6B). The effect of p35 on Pin1-Tau interaction was inhibited by the addition of roscovitine to the culture media. Finally, the effect of desalkylflurazepam on Pin1-Tau interaction was enhanced by more than 3-fold in cells overexpressing p35 as compared with mock-transfected PCA reporter cells (Fig. 6C). Taken together, these results suggest that GABA<sub>A</sub> activity modulates Tau phosphorylation at the AT8 epitope in a Cdk5-dependent manner.

DISCUSSION

Regulation of Tau phosphorylation is a dynamic and tightly controlled event in neurons. Deregression of this system may result in development of tauopathies, such as Alzheimer disease or frontotemporal dementia. Interestingly, recent studies have identified novel functions for Tau beyond the conventional regulation of microtubules (reviewed in Ref. 4). Detailed understanding of the complex protein-protein interactions of Tau is becoming increasingly important for development of Tau-targeting therapies for many aging-related CNS disorders. We have developed a novel protein fragment complementation-based assay system for studying Tau PPIs in live cells. Because Pin1 is a critical regulator of Tau dephosphorylation in neurons (37), we first focused on Pin1-Tau interaction as a dynamic live cell PPI reporter. Based on the data reported here, we conclude that hGLuc-based PCA suits well for studying PPIs of Tau in a live cell assay. Functional validation data showed that Pin1-Tau PCA is responsive to physiological stimulation (increased GSK3β level/activity) and inhibition of Pin1 (juglone). Moreover, the proof-of-concept screen of the focused pharmaceutical library showed that the PCA method is capable of identifying compounds increasing and decreasing the Pin1-Tau interaction. Folic acid, one of the few compounds that decreased the Pin1-Tau interaction, has previously been shown to affect Tau phosphorylation by promoting methylation and maturation of the PP2A complex (25, 38). This is consistent with our data showing that the Pin1-Tau PCA signal levels correlate with Tau phosphorylation and that folic acid reduced Pin1-Tau signal in cells. Interestingly, higher folate intake in the
GABA\textsubscript{A} Receptor Activation Modulates Tau Phosphorylation

elderly (>65 years) has been associated with lower incidence of AD (39).

Unexpectedly, the proof-of-concept screen identified several GABA\textsubscript{A} receptor modulators belonging to the barbiturate and benzodiazepine classes as hit compounds increasing Pin1-Tau interaction. Previously, Tau has been functionally linked to NMDA receptor trafficking (reviewed in Refs. 4 and 40). Other neurotransmitter receptor systems have so far not been implicated in the regulation of Tau phosphorylation with the exception of dopamine. In SK-N-MC cells and striatal neurons, Tau was phosphorylated at Ser-199/Ser-202 in response to dopamine D1 receptor activation in a Ca\textsuperscript{2+}- and PKA-dependent manner (41, 42). Interestingly, we found that GABA\textsubscript{A} receptor activators, as well as a dopamine D1/D2 receptor antagonist, increased Pin1-Tau interaction and Tau phosphorylation at Ser-199/Ser-202/Thr-205 (in case of GABA\textsubscript{A} activation; the dopamine D1/D2 antagonist was not analyzed further in this study). In addition, Tau phosphorylation was previously shown to be modulated by 3,4-methylenedioxyxymethamphetamine ("ecstasy") in the hippocampus (43) and by various anesthetics in the cortex and hippocampus (28). Interestingly, reversible PHF-like Tau hyperphosphorylation has been shown to occur in hibernating mammals (44, 45). This suggests that Tau phosphorylation is not only responsive to modulation of several neurotransmitter systems and CNS-active drugs but may be more generally associated with the level of neuronal activity.

The GABA\textsubscript{A} receptors compose a family of ligand-gated Cl\textsuperscript{-} channels, formed by the pentameric assembly of multiple subunits. Large number of GABA\textsubscript{A}Rs with different subunit composition and distinct physiological and pharmacological properties are differentially expressed throughout the brain (23). Moreover, different GABA\textsubscript{A}Rs can be targeted to different subcellular regions. For example, GABA\textsubscript{A}Rs composed of \alpha\textsubscript{1}, \alpha\textsubscript{2}, \alpha\textsubscript{3}, or \alpha\textsubscript{5} subunits associated with \beta and \gamma subunits are benzodiazepine-sensitive, are largely synaptically located, and mediate most phasic inhibition in the brain. By contrast, those GABA\textsubscript{A}Rs composed of \alpha\textsubscript{4} or \alpha\textsubscript{6} subunits together with \beta and \delta subunits form a distinct population of mostly extrasynaptic receptors that mediate tonic inhibition and are insensitive to benzodiazepine modulation (46). Our data showing that benzodiazepines can induce Tau phosphorylation in mature synaptically connected neurons suggest that these effects are mediated mostly by synaptic GABA\textsubscript{A} receptors.

Synaptic GABA\textsubscript{A}R complexes associate with the major inhibitory synapse scaffolding protein gephyrin that is directly linked to MTs (47, 48). As a MT-binding protein, Tau could participate in dynamic regulation of clustering or trafficking of GABA\textsubscript{A}Rs at the inhibitory synapses (49) and consequently also be a subject of modulation by GABAergic synaptic signaling. GSK3\textbeta, a major Tau kinase, was recently found to regulate GABAergic synapse formation via phosphorylation of gephyrin (50). Our data suggest that Cdk5 but not GSK3\textbeta is involved in GABA\textsubscript{A}R-induced phosphorylation of Tau. This is reminiscent of the recent data from hibernating mammals, where Cdk5 instead of GSK3\textbeta was shown to play a more important role in increased Tau phosphorylation (45).

Proline-directed phosphorylation of 14 serine-proline and threonine-proline motifs located in the proline-rich regions of Tau appears to be a central mechanism of regulation of its cellular functions. Pin1 facilitates Tau dephosphorylation by PP2A (16). Interestingly, gephyrin also undergoes proline-directed phosphorylation followed by Pin1-mediated prolyl isomerization that appears to be important for its ability with glycine receptors (51). It has been proposed that prolyl \textit{cis-trans}-isomerization can act as a molecular timer to help control the amplitude and duration of diverse cellular processes (52). Pin1-mediated regulation of both gephyrin scaffold and Tau could be used to regulate the timing or duration of GABA\textsubscript{A}R trafficking signals in the inhibitory synapses. Phosphorylation of GABA\textsubscript{A}R subunit \beta3 appears to be an important regulator of GABA\textsubscript{A}R function. PP2A associates with and dephosphorylates GABA\textsubscript{A}R-\beta3 (53). Interestingly, PP1 rather than PP2A seems to play a major role in gephyrin dephosphorylation (54). Our data suggest that GABA\textsubscript{A}R activation results in increased phosphorylation of Tau and increased Pin1 but reduced PP2A association with Tau. Based on our data, GABA\textsubscript{A} modulators do not directly inhibit the enzyme activity of PP2A \textit{in vitro}. However, our PCA data suggest that less PP2A associates with Tau in cells exposed to GABA\textsubscript{A}R-active sedatives. In polarized cells like neurons, there may be significant compartment-specific differences in PP2A levels and activity. For example, phosphorylation of neurofilament proteins is differentially regulated in cell bodies and axons by a Pin1-PP2A-dependent mechanism (55). Moreover, increased GABA\textsubscript{A}R activity could recruit PP2A for \beta3 subunit dephosphorylation and receptor desensitization. It is possible that a strong and persistent GABA\textsubscript{A}R activating stimuli could result in recruitment of PP2A to the cell surface, reducing the availability of PP2A for Tau dephosphorylation.

BZs are widely used sedatives, hypnotics, anxiolytics, and anticonvulsants, and their potent sedative properties are routinely utilized in presurgical anesthesia. Because of their adverse effects, such as development of tolerance and addiction, BZ have not been approved for long term use. Moreover, BZ can produce anterograde amnesia, a mechanistically poorly understood adverse affect of BZ recognized more than four decades ago (reviewed in Ref. 56). The degree and duration of anterograde amnesia depends on several factors, such as the particular BZ taken, dosage, and route of administration. Interestingly, postoperative cognitive dysfunction may be partially explained by anesthesia-induced Tau hyperphosphorylation (28). Ethanol shares several pharmacological actions with barbiturates and BZs and can, among other effects, cause anterograde amnesia (57). Exposure of developing neurons to ethanol promotes Tau phosphorylation at Ser-199/Ser-202/Thr-205 (58). All of the above-mentioned agents act mostly or partially through GABA\textsubscript{A} receptor. The identification of Tau phosphorylation at the AT8 epitope, reportedly one of the priming sites (10), as a downstream target of GABA\textsubscript{A} activation raises intriguing questions about the mechanistic connections between chronic sedative or ethanol use, anterograde amnesia, and possibly risk of dementia. Our data suggest that, in cultured neurons, Tau phosphorylation at the AT8 epitope remains at an elevated level for at least 24 h after the washout of GABA\textsubscript{A} activating drugs. BZs are commonly used in clinical practice to reduce behavioral and psychological symptoms associated with dementia, such as agitation and aggression, as well as sleep dis-
turbances. Therefore, more detailed studies are needed to address whether chronic sedative use (particularly BZs with long elimination half-lives) could accelerate the progression of dementia.

Acknowledgments—The plasmids encoding the split hGLuc fragments were a kind gift from Prof. Stephen Michnick (Université de Montréal, Montreal, Canada), and the antibodies AT8 and TG3 were from Dr. Jin-Jing Pei (Karolinska Institutet, Stockholm, Sweden).

REFERENCES

1. Lee, V. M., Goedert, M., and Trojanowski, J. Q. (2001) Neurodegenerative tauopathies. Annu. Rev. Neurosci. 24, 1121–1159
2. Ballatore, C., Lee, V. M., and Trojanowski, J. Q. (2007) Tau-mediated neurodegeneration in Alzheimer’s disease and related disorders. Nat. Rev. Neurosci. 8, 663–672
3. Hutton, M., Lendon, C. L., Rizzu, P., Baker, M., Froelich, S., Houlden, H., Pickering-Brown, S., Chakraverty, S., Isaacs, A., Grover, A., Hackett, J., Adamson, J., Lincoln, S., Dickson, D., Davies, P., Petersen, R. C., Stevens, M., de Graaff, E., Wauters, E., van Baren, J., Hillebrand, M., Joosse, M., Kwon, J. M., Nowotny, P., Che, L. K., Norton, J., Morris, J. C., Reed, A. L., Trojanowski, J., Basun, H., Lannfelt, L., Neystat, M., Fahn, S., Dark, F., Tannenberg, T., Dodd, P. R., Hayward, N., Kwock, J. B., Schofield, P. R., Andreadi, A., Snowden, J., Craufurd, D., Neary, D., Owen, F., Oostra, B. A., Hardy, J., Goate, A., van Swieten, J., Mann, D., Lynch, T., and Heutink, P. (1998) Association of missense and 5′-splice-site mutations in Tau with the inherited dementia FTDP-17. Nature 393, 702–705
4. Morris, M., Maeda, S., Vossel, K., and Mucke, L. (2011) The many faces of Tau. Neuron 70, 410–426
5. Mandelkow, E. M., Stamer, K., Vogel, Y., Thies, E., and Mandelkow, E. (2003) Clogging of axons by Tau. Inhibition of axonal traffic and starvation of synapses. Neuroscience 114, 1273–1279
6. Dixit, R., Ross, J. L., Goldman, Y. E., and Holzbaur, E. L. (2008) Differential regulation of dynem and kinesin motor proteins by tau. Science 319, 1086–1089
7. Hoover, B. R., Reed, M. N., Su, J., Penrod, R. D., Kotlikin, L. A., Grant, M. K., Pittsick, R., Carlson, G. A., Lanier, L. M., Yuan, L. L., Ashe, K. H., and Liao, P. (2010) Tau mislocalization to dendritic spines mediates synaptic dysfunction independently of neurodegeneration. Neuron 68, 1067–1081
8. Ittner, L. M., Ke, Y. D., Delerue, F., Bi, M., Gladbach, A., van Eersel, J., Wolfling, H., Chieng, B. C., Christie, M. J., Napier, I. A., Eckert, A., Staufenbiel, M., Hardeman, E., and Götz, J. (2010) Dendritic function of Tau mediates amyloid-beta toxicity in Alzheimer’s disease mouse models. Cell 142, 387–397
9. Luna-Muñoz, J., Chávez-Macías, L., García-Sierra, F., and Mena, R. (2007) Early stages of Tau conformational changes are related to the appearance of a sequence of specific phospho-dependent Tau epitopes in Alzheimer’s disease. J. Alzheimer’s Dis. 12, 365–375
10. Bertrand, J., Plouffe, V., Sénéchal, P., and Leclerc, N. (2010) The pattern of synapses. Brain Res. Dev. Brain Res. 202, 39–43
11. Leclerc, N., Bélanger, M., Hardeman, E., and Götz, J. (2010) Dendritic function of Tau masks stress-induced dephosphorylation of Tau in neurons. Implication in a pathological mechanism related to Alzheimer disease. J. Neurosci. 30, 9045–9054
12. Plattner, F., Angelo, M., and Giese, K. P. (2006) The many faces of gap between pathophysiology and molecular level.

GABA_{A} Receptor Activation Modulates Tau Phosphorylation
GABA<sub>A</sub> Receptor Activation Modulates Tau Phosphorylation

34. Louis, J. V., Martens, E., Borghgraef, P., Lambrecht, C., Sents, W., Longin, S., Zwaenepoel, K., Pijnenborg, R., Landrieu, I., and Lippens, G. (2011) Mice lacking phosphatase PP2A subunit PR61/B′/δ (Ppp2r5d) develop spatially restricted tauopathy by deregulation of CDK5 and GSK3β. *Proc. Natl. Acad. Sci. U.S.A.* **108**, 6957–6962

35. Lew, J., Huang, Q. Q., Qi, Z., Winkfein, R. J., Aebersold, R., Hunt, T., and Wang, J. H. (1994) A brain-specific activator of cyclin-dependent kinase 5. *Nature* **371**, 423–426

36. Tsai, L. H., Delalle, I., Cavin, V. S., Jr., Chae, T., and Harlow, E. (1994) p35 is a neural-specific regulatory subunit of cyclin-dependent kinase 5. *Nature* **371**, 419–423

37. Lim, J., Balastik, M., Lee, T. H., Nakamura, K., Liou, Y. C., Sun, A., Finn, G., Pastorino, L., Lee, V. M., and Lu, K. P. (2008) Pin1 has opposite effects on wild-type and P301L Tau stability and tauopathy. *J. Clin. Invest.** 118**, 1877–1889

38. Sontag, E., Nunbhakdi-Craig, V., Sontag, J. M., Diaz-Arrastia, R., Ogris, E., Dayal, S., Lentz, S. R., Arning, E., and Bottiglieri, T. (2007) Protein phosphatase 2A methyltransferase links homocysteine metabolism with tau and amyloid precursor protein regulation. *J. Neurosci.** 27**, 2751–2759

39. Luchsinger, J. A., Tang, M. X., Miller, J., Green, R., and Mayeux, R. (2007) Higher folate intake to lower risk of Alzheimer disease in the elderly. *Arch. Neurol.** 64*, 86–92

40. Ittner, L. M., and Gotz, J. (2011) *Nat. Rev. Neurosci.* **12**, 65–72

41. Lebel, M., and Cyr, M. (2011) Molecular and cellular events of dopamine D1 receptor-mediated Tau phosphorylation in SK-N-MC cells. *Synapse** 65*, 69–76

42. Lebel, M., Patenaude, C., Allyson, J., Massicotte, G., and Cyr, M. (2009) Dopamine D1 receptor activation induces Tau phosphorylation via CdK5 and GSK3 signaling pathways. *Neuropharmacology** 57*, 392–402

43. Busceti, C. L., Biagiioni, F., Rizzoli, B., Battaglia, G., Storto, M., Cinque, C., Molinaro, G., Gradini, R., Caricasole, A., Canudas, A. M., Bruno, V., Nicoletti, F., and Fornai, F. (2008) Enhanced Tau phosphorylation in the hippocampus of mice treated with 3,4-methylenedioxymethamphetamine (‘ecstasy’). *J. Neurosci.** 28*, 3234–3245

44. Arendt, T., Triester, J., Strijkstra, A. M., Hut, R. A., Rüdiger, J., Van der Zee, E. A., Harkany, T., Holzer, M., and Härtig, W. (2003) Reversible paired helical filament-like phosphorylation of Tau is an adaptive process associated with neuronal plasticity in hibernating animals. *J. Neurosci.** 23*, 6972–6981

45. Triester, J. T., Bullmann, T., Kohl, F., Toien, Ö., Brückner, M. K., Härtig, W., Barnes, B. M., and Arendt, T. (2011) The physiological link between metabolic rate depression and Tau phosphorylation in mammalian hibernating animals. *PLoS One** 6*, e14530

46. Brünig, I., Scotti, E., Sidler, C., and Fritschy, J. M. (2002) Intact sorting, targeting, and clustering of γ-aminobutyric acid A receptor subtypes in hippocampal neurons *in vitro*. *J. Comp. Neurol.** 443*, 43–55

47. Prior, P., Schmitt, B., Grenningloh, G., Pribilla, I., Multhaup, G., Beyreuther, K., Maulet, Y., Werner, P., Langosch, D., and Kirsch, I. (1992) Primary structure and alternative splice variants of gephyrin, a putative glycine receptor–tubulin linker protein. *Neuron** 8*, 1161–1170

48. Esrich, C., Lores, M., Benson, J. A., Fritschy, J. M., and Lüscher, B. (1998) Postsynaptic clustering of major GABA<sub>A</sub> receptor subtypes requires the γ2 subunit and gephyrin. *Nat. Neurosci.** 1*, 563–571

49. Jacob, T. C., Moss, S. J., and Jurd, R. (2008) GABA<sub>A</sub> receptor trafficking and its role in the dynamic modulation of neuronal inhibition. *Nat. Rev. Neurosci.** 9*, 331–343

50. Tyagajaran, S. K., Ghosh, H., Yévenes, G. E., Nikonenko, I., Ebeling, C., Schwerdel, C., Sidler, C., Zeilhofer, H. U., Gerrits, B., Muller, D., and Fritschy, J. M. (2011) Regulation of GABAergic synapse formation and plasticity by GSK3β-dependent phosphorylation of gephyrin. *Proc. Natl. Acad. Sci. U.S.A.** 108*, 379–384

51. Zita, M. M., Marchionni, I., Bottos, E., Righi, M., Del Sal, G., Cherubini, E., and Zacchi, P. (2007) Post-phosphorylation prolyl isomerization of gephyrin represents a mechanism to modulate glycine receptors function. *EMBO J.** 26*, 1761–1771

52. Lu, K. P., Finn, G., Lee, T. H., and Nicholson, L. K. (2007) Prolyl cis–trans isomerization as a molecular timer. *Nat. Chem. Biol.** 3*, 619–629

53. Jovanovic, J. N., Thomas, P., Kittler, J. T., Smart, T. G., and Moss, S. J. (2004) Brain-derived neurotrophic factor modulates fast synaptic inhibition by regulating GABA<sub>A</sub> receptor phosphorylation, activity, and cell-surface stability. *J. Neurosci.** 24*, 522–530

54. Bausen, M., Weltzien, F., Betz, H., and O’Sullivan, G. A. (2010) Regulation of postsynaptic gephyrin cluster size by protein phosphatase 1. *Mol. Cell Neurosci.** 44*, 201–209

55. Rudrabhatla, P., Albers, W., and Pant, H. C. (2009) Peptidyl-prolyl isomerization 1 regulates protein phosphatase 2A-mediated topographic phosphorylation of neurofilament proteins. *J. Neurosci.** 29*, 14869–14880

56. Curran, H. V. (1991) Benzodiazepines, memory and mood. A review. *Psy- chopharmacology** 105*, 1–8

57. Fadda, F., and Rossetti, Z. L. (1998) Chronic ethanol consumption. From neuroadaptation to neurodegeneration. *Prog. Neurobiol.** 56*, 385–431

58. Saito, M., Chakraborty, G., Mao, R. F., Paik, S. M., Vadasz, C., and Saito, M. (2010) Tau phosphorylation and cleavage in ethanol-induced neurodegeneration in the developing mouse brain. *Neurochem. Res.** 35*, 651–659